Purdue subsidiary buys non-opioid pain prospect from PureHealth

With Purdue Pharma plotting a future beyond the bankruptcy proceedings now consuming the company, its drug development subsidiary Imbrium Therapeutics has secured global rights to a drug candidate that could play a role in the move beyond opioids.

Imbrium has bought a non-opioid treatment for interstitial cystitis/bladder pain syndrome (IC/BPS) from PureTech Health.